Journal article icon

Journal article

Developmental dynamics of voltage-gated sodium channel isoform expression in the human and mouse brain

Abstract:
AbstractBackgroundGenetic variants in the voltage-gated sodium channelsSCN1A,SCN2A,SCN3A, andSCN8Aare leading causes of epilepsy, developmental delay, and autism spectrum disorder. The mRNA splicing patterns of all four genes vary across development in the rodent brain, including mutually exclusive copies of the fifth protein-coding exon detected in the neonate (5N) and adult (5A). A second pair of mutually exclusive exons is reported inSCN8Aonly (18N and 18A). We aimed to quantify the expression of individual exons in the developing human brain.MethodsRNA-seq data from 783 human brain samples across development were analyzed to estimate exon-level expression. Developmental changes in exon utilization were validated by assessing intron splicing. Exon expression was also estimated in RNA-seq data from 58 developing mouse neocortical samples.ResultsIn the mature human neocortex, exon 5A is consistently expressed at least 4-fold higher than exon 5N in all four genes. ForSCN2A,SCN3A, andSCN8A, a brain-wide synchronized 5N to 5A transition occurs between 24 post-conceptual weeks (2nd trimester) and 6 years of age. In mice, the equivalent 5N to 5A transition begins at or before embryonic day 15.5. InSCN8A, over 90% of transcripts in the mature human cortex include exon 18A. Early in fetal development, most transcripts include 18N or skip both 18N and 18A, with a transition to 18A inclusion occurring from 13 post-conceptual weeks to 6 months of age. No other protein-coding exons showed comparably dynamic developmental trajectories.ConclusionsExon usage inSCN1A,SCN2A,SCN3A, andSCN8Achanges dramatically during human brain development. These splice isoforms, which alter the biophysical properties of the encoded channels, may account for some of the observed phenotypic differences across development and between specific variants. Manipulation of the proportion of splicing isoforms at appropriate stages of development may act as a therapeutic strategy for specific mutations or even epilepsy in general.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s13073-021-00949-0

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9393-2645
More by this author
Role:
Author
ORCID:
0000-0002-9505-8090
More by this author
Role:
Author
ORCID:
0000-0003-3523-0247
More by this author
Role:
Author
ORCID:
0000-0003-0883-7000


More from this funder
Funder identifier:
10.13039/501100003725
Grant:
NRF-2020R1C1C1003426
More from this funder
Funder identifier:
10.13039/100000065
Grant:
R01 NS099099
More from this funder
Funder identifier:
10.13039/100000025
Grant:
R01 MH111662
More from this funder
Funder identifier:
10.13039/100014370
Grant:
574598


Publisher:
BioMed Central
Journal:
Genome Medicine More from this journal
Volume:
13
Issue:
1
Pages:
135-135
Article number:
135
Publication date:
2021-08-23
DOI:
EISSN:
1756-994X
ISSN:
1756-994X


Language:
English
Keywords:
Pubs id:
1329140
Local pid:
pubs:1329140
Source identifiers:
W3194919165
Deposit date:
2026-05-01
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP